Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy

References

• Tedeschi A, Picardi P, Ferrero S, et al. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. Leuk Lymphoma. 2015;56(9):1–8.
   Web of Science ®Google Scholar
• Annibali O, Petrucci MT, Martini V, et al. Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis. Cancer. 2005 Feb 1;103(3):582–587.
   Web of Science ®Google Scholar
• Waldenström JG. Macroglobulinemia–a review. Haematologica. 1986;71:437–441.
   Web of Science ®Google Scholar
• Dimopoulos MA, Alexanian R. Waldenstrom’s macroglobulinemia. Blood. 1994;83:1452–1459.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Gertz MA, Fonseca R. Waldenström macroglobulinaemia. Lancet Oncol. 2003;4:679–685.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al. Waldenström’s macroglobulinemia: clinical features, complications, and management. J Clin Oncol. 2000;18:214–226.
   PubMed Web of Science ®Google Scholar
• International Waldenström Macroglobulinema Foundation. Information on the disease. Available from: https://www.iwmf.com/
   Google Scholar
• Buske C, Leblond V, Dimopoulos M, et al.; ESMO guidelines Working Group. Waldenstrom’s macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi155–vi59.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Palomba ML, Advani R, et al. Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. Ther Adv Hematol. 2016;7:179–186.
   Web of Science ®Google Scholar
• Castillo JJ, Olszewski AJ, Kanan S, et al. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the surveillance, epidemiology and end results database. Br J Haematol. 2015;169:81–89.
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Kapoor P, Ansell SM, et al. Ibrutinib for the treatment of Waldenström macroglobulinemia. Expert Rev Hematol. 2015 Oct;8(5):569–579.
   PubMed Web of Science ®Google Scholar
• Wujcik D. Targeted therapy. In: Yarbro CH, Wujcik D, Gobel BH, editors. Cancer nursing: principles and practice. Sudbury (MA): Jones and Bartlett; 2011. p. 561–583.
   Google Scholar
• Cameron F, Sanford M. Ibrutinib: first global approval. Drugs. 2014 Feb;74(2):263–271.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Imbruvica® (ibrutinib) capsules, for oral use: highlights of prescribing information. Revised 01/2015. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205552s002lbl.pdf
   Google Scholar
• European Medicine Agency. Imbruvica® (ibrutinib). Product information. Product information Imbruvica -EMEA/H/C/003791 -II/0025. [ cited 2017 Mar 31]. Retrieved from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003791/human_med_001801.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. Engl J Med. 2015;372:1430–1440.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Dimopoulos MA. Current therapy guidelines for Waldenstrom’s macroglobulinaemia. Best Pract Res Clin Haematol. 2016;29(2):194–205.
   Web of Science ®Google Scholar
• Tedeschi A, Ricci F, Goldaniga MC, et al. Cyclophosphamide, and rituximab in salvage therapy of Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013;13:231–234.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Am J Hematol. 2010;85:670–674.
   PubMed Web of Science ®Google Scholar
• Buske C, Hoster E, Dreyling M, et al.; German Low-Grade Lymphoma Study Group. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009;23(1):153–161. https://www.nature.com/leu/journal/v23/n1/full/leu2008261a.html
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122:3276–3282. 10.1182/blood-2013-05-503862
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25:3344–3349. 10.1200/JCO.2007.10.9926
   PubMed Web of Science ®Google Scholar
• Rummel MJ1, Niederle N, Maschmeyer G, et al. Study group indolent Lymphomas (StiL).Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210.
   PubMed Web of Science ®Google Scholar
• ISTAT. Tavole di Mortalità; 2016. Available from: www.istat.it
   Google Scholar
• Ministero Salute. Remunerazione prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. Decreto 18-Oct-2012. Available from: http://www.salute.gov.it/portale/temi/p2_6.jsp?id=3662&area=programmazioneSanitariaLea&menu=vuoto
   Google Scholar
• Farmadati. Compendio farmaceutico. Available from: www.farmadati.it
   Google Scholar
• Baker JJ. Activity-based costing and activity-based management for healthcare. Gaithersburg (MD): Apen; 1998.
   Google Scholar
• Roffia P. Il controllo di gestione activity-based. Torino: Giappichelli; 2002.
   Google Scholar
• Innes J, Mitchell F. Activity-based cost management. London: CIMA; 1991.
   Google Scholar
• Fattore G. Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. Pharmacoeconomics Ital Res Articles. 2009;11:83–93.
   Google Scholar
• Messori A, Santarlasci B, Trippoli S, et al. Controvalore economico del farmaco e beneficio clinico: stato dell’arte della metodologia e applicazione di un algoritmo farmacoeconomico. Pharmacoeconomics-Ital Res Articles. 2003;5(2):53–67.
   Google Scholar
• Drummond MF, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36–42.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Trotman J, Tedeschi A, et al. iNNOVATE study group and the European consortium for Waldenström’s Macroglobulinemia. Ibrutinib for patients with rituximab-refractory Waldenström’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18(2):241–250.
   PubMed Web of Science ®Google Scholar
• Treon SP, Yang G, Zhou Y, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012 Aug 30;367(9):826–833. DOI:10.1056/NEJMoa1200710
   PubMed Web of Science ®Google Scholar
• Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood. 2013;122(7):1222–1232.
   PubMed Web of Science ®Google Scholar
• Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom’s macroglobulinemia. Ann Oncol. 2004;15(10):1481–1483. 10.1093/annonc/mdh403
   PubMed Web of Science ®Google Scholar
• Gertz M. Waldenström macroglobulinemia: my way. Leuk Lymphoma. 2013;54(3):464–471.
   PubMed Web of Science ®Google Scholar
• Leleu X, Roccaro AM, Moreau AS, et al. Waldenstrom macroglobulinemia. Cancer lett. 2008;270(1):95–107.
   Web of Science ®Google Scholar
• Garcia-Sanz R, Ocio EM. Novel treatment regimens for Waldenström’s macroglobulinemia. Expert Rev Hematol. 2010;3(3):339–350.
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Treon SP, Castillo JJ. Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis. Oncologist. 2016 Jul 29. pii: theoncologist.2016-0126. [Epub ahead of print] http://theoncologist.alphamedpress.org/content/21/11/1377
   Web of Science ®Google Scholar